Second Lawsuit Hits DEA Over Medical Marijuana Rules
Photo by Cova Software via Unsplash.
November 29 is days away, and two groups of medical marijuana operators have now gone to court to try to stop the Drug Enforcement Administration's new supply-chain rules before they bite.
Schedule III was supposed to be the easier path for medical operators. What is drawing fire is not the rescheduling itself but how DEA is carrying it out, and the restrictions it is attaching to state-licensed businesses along the way.
One caveat up front: the second lawsuit, filed by Pennsylvania companies, is known to us only through early coverage. The court and the plaintiffs' names were not confirmed at the time of writing, so treat those details as open.
Key takeaways
- Four Pennsylvania vertically integrated medical cannabis companies sued the DEA, the second legal challenge to its rescheduling-related guidance in two days.
- DEA guidance sets a November 29 deadline for sourcing from and selling to only registered operators or timely applicants.
- State regulators say the guidance splits most medical markets in two, while petitioners argue it exceeds DEA authority and skipped notice and comment.
What the Pennsylvania Companies Are Challenging
Four Pennsylvania companies filed suit on Thursday, apparently November 19, one day after the first challenge landed. They operate vertically integrated businesses, meaning each handles cultivation, processing and dispensing under one roof. That structure matters here because a break anywhere in the chain can stall the whole operation.
The suit goes after restrictions DEA is placing on marijuana businesses alongside the Trump administration's federal rescheduling move. Industry observers and state regulators have warned that those restrictions could upend state-licensed markets.
Coverage of the DEA orders at issue says the agency generally treats some states' allowance of adult-use sales as a violation of two things. One is the Controlled Substances Act's closed system for medical access to scheduled drugs. The other is U.S. treaty obligations.
That framing is the pressure point. If a state runs both medical and adult-use programs, DEA's reading puts its medical licensees in an awkward spot under the new rules.
To be plain about what we do not know: available reporting does not name the court or the four plaintiffs. Until the petition itself is reviewed, anything beyond the basic outline is unconfirmed.
The First Lawsuit and Its Three Arguments
The first challenge came a day earlier, on November 18. Standard Wellness Utah, Arizona's Verde Americano and Oklahoma's NW Confections OK filed a petition for review, reportedly in the U.S. Court of Appeals for the D.C. Circuit. Their target is DEA's October 30 guidance, titled DEA Medical Marijuana Timely Applicant Information.
The petition argues the guidance is unlawful on three grounds:
- It contradicts the rescheduling order Attorney General Todd Blanche issued in April, and it exceeds DEA's authority.
- It is a legislative rule issued without notice and comment.
- It upends settled expectations by splitting state markets as of a set date.
The second argument is the classic administrative-law play. If a court agrees the guidance binds operators like a regulation, DEA skipped a required step by not taking public comment first.
The petitioners also lean on 21 C.F.R. § 1301.13(k)(7). They read it, together with the April order, to let timely applicants operate under their state licenses while applications are pending, with no extra trading-partner condition.
That reading is the petitioners' argument, and it is disputed. DEA evidently sees the rule differently, and the court will have to decide which interpretation holds.
The November 29 Deadline and Supply-Chain Fallout
Last month, DEA announced it had granted federal registration and protections to hundreds of medical marijuana businesses in line with rescheduling. The exact count has not been confirmed in the sources available.
The new guidance sets a hard line: by November 29, cannabis companies must source product only from, and sell only to, operators that are registered or are timely applicants. A timely applicant is simply an unregistered business that applied on time.
The trouble is geography. State markets prohibit interstate commerce, so the filing says operators are entirely dependent on intrastate markets. A licensee cannot shop for a registered supplier in the next state. If the in-state partner is not on the right list, there is nobody else to call.
The petition says the damage has started. Reported effects include:
- Partners quarantining product
- Partners demanding proof of DEA status
- Orders being paused
Petitioners have asked the court to pause the supply-chain rules before the deadline. Whether any judge acts in that window is the single most important open question in the whole fight.
Why State Regulators Say Markets Are Splitting
State regulators have been saying the same thing for weeks, and they say it bluntly. The head of the association representing state cannabis regulators, identified only as Schauer in available coverage, says DEA's instruction has split most state medical marijuana markets in two.
On one side sit DEA registrants and timely applicants. On the other are state licensees who are neither, still fully legal under state law but now cut off from the first group.
She also describes orders to show cause delivered to DEA applicants in at least seven states or jurisdictions. According to her account, those orders say state policies will prevent registration. These are claims from state regulators, not independently verified findings, and DEA has its own view of what those orders say.
Some DEA documents also single out state laws that let certain patients access medical cannabis without a doctor's written recommendation. That is a notable target, since it touches how states define a medical patient at all.
For regulators, the worry is practical. A market split by federal status is hard to supervise, hard to supply and confusing for patients at the counter.
Related Litigation and What to Watch Next
Neither new suit stands alone. A separate D.C. Circuit challenge to the underlying rescheduling order is pending. Petitioners there include Smart Approaches to Marijuana, a drug-testing association and the biopharma firm MMJ International Holdings.
A stay request in that case was denied, so Schedule III remains in effect while the court reviews the merits. That is a useful signal: this court has already declined one request to freeze the rule, though a stay of DEA's guidance is a different ask.
Here is what to watch:
- Whether any court sets a briefing schedule
- Whether a stay ruling arrives before November 29
- Whether the Pennsylvania plaintiffs and court are identified
Dale's Report describes DEA's selective approach to states with both medical and adult-use markets as creating a patchwork. Expect that patchwork to matter in every filing.
Legality and licensing rules differ by state, and the federal picture is shifting week to week. Confirm current requirements with your state regulator before making sourcing or purchasing decisions.
The real test is whether a court acts before November 29. Without a stay, operators will have to make sourcing decisions under uncertainty, choosing partners based on federal status they cannot always verify.
Underneath the procedural arguments, the dispute is less about Schedule III itself than about who decides how it is implemented, and by what process. Notice and comment is not a technicality here. It is the question of whether a guidance document can reshape state markets overnight.
Operators and patients should watch their state regulator's guidance closely and confirm local rules rather than assume federal protection applies the same way everywhere. It currently does not.
Sources
- DEA Faces Second Lawsuit From More Medical Marijuana Businesses That Say Rescheduling Rules Could Upend State Markets - Marijuana Moment
- Medical Marijuana Companies Sue DEA Over Nov. 29 Rule
- Back to the Deadline: Medical Marijuana Operators Ask a Court to Pause DEA’s Supply-Chain Rules
- Medical Marijuana Companies Sue DEA In Federal Court Over Restrictions It Imposed For Rescheduling Protections - Marijuana Moment
- Medical Marijuana Companies Sue DEA In Federal Court Over Restrictions - The Dales Report
- DEA Marijuana Rescheduling Plan Leaves Regulators And Patients In Limbo



